A rogue who thinks badly about it: The cases of testicular cancer seem to be largely vaccinated athletes keep increasing. After professional soccer players Timo Baumgartl (26), Marco Richter (24) and Sebastian Haller (28), 28-year-old Jean-Paul Boetius from Hertha BSC received the bad diagnosis. Also in handball was recently a case public: 26-year-old Lukas Hüller. How fortunate that BioNTech announced in February that it was working on an mRNA preparation against testicular cancer.
The accumulation of cases of illness cannot be denied even for the mainstream. Of course, one always strives for explanations: according to tz.de, for example, everything is pure random. True to the motto: When you hear hoofbeats, think zebras, not horses. Or something like that.
BioNTech is working on testicular cancer mRNA drugs
The fact that the carcinogenicity of the corona vaccinations has never been tested is no longer news. After the mass vaccinations, numerous physicians have noticed a noticeable increase in cancer cases in their practices, but official investigations seem simply undesirable. Statements by the BioNTech Supervisory Board Chairman from February this year appear in a completely new light in view of these developments: As is well known, the controversial manufacturer intends to develop a whole range of cancer drugs based on mRNA technology – and its initial efforts are focused on the gene therapy treatment of testicular cancer, of all things. From a financial point of view, this type of cancer is usually not very exciting for the pharmaceutical industry, it was said at the time. So the competition is very limited. No wonder: testicular cancer is actually a very rare disease.
It was claimed at the time that it was part of BioNTech’s “ethical approach” to also rely on forms of therapy “that may be economically less interesting for other pharmaceutical companies”. Of course, in view of a possible case explosion, that could change: then a new drug would certainly still be able to make good profits.
A little development time was granted in February: By 2027, however, “several products from Biontech should come onto the market as cancer therapies,” according to the chairman of the supervisory board ntv. In view of the fact that a stable database is no longer necessary for approval procedures, it could presumably be much faster.